Table 1. Characteristics of included studies.

References	Patients’ Status/Treatment Stage	Sample Size	Age (yrs)/Country	CART Intervention (training parameters)	Length (wks)	Setting/Cancer Stage	BMI ± SD (kg/m2)	Outcome Measures
(Dieli-Conwright et al., 2018)	BC survivors After treatment	N: 91 EX: 46 C: 45	EX: 52.8 ± 10.6 CO: 53.6 ± 10.1 United States	AE: 2–3 d/wk, 150 min, 40%–50% HRR; RT: 3 d/wk, 40%–50% 1-RM	16	Supervised/Stage: I, II, III	EX: 33.1 ± 5.7 C: 33.4 ± 5.2	HDL-C, TC, TG, CRP, TNF-α, IL-6, LEP, BM, BF, FM, FFM, WC, HC, QoL, FA
(Dieli-Conwright et al., 2018) Cont.	BC survivors After treatment	N: 20 EX: 10 C: 10	EX: 53.0 ± 10.0 CO: 55.0 ± 4.5 United States			Supervised/Stage: I, III	EX: 33.5 ± 5.7 C: 33.3 ± 8.7	BF, ADPN, IL-8, LDL
(Dieli-Conwright et al., 2018) Cont.	BC survivors After treatment	N: 100 EX: 50 C: 50	Total: 52 ± 10.4 United States	AE: 2 d/wk, 80 min, 65%–80% HRmax; RT: 2–3 d/wk, 60% 1-RM	16	Supervised/Stage: 0, III	Total BMI: 33.5 ± 5.5	SQ
(Dieli-Conwright et al., 2019)	BC survivors After treatment	N: 56 EX: 29 C: 27	EX: 46.9 ± 10.2 C: 46.7 ± 10.0 United States	AE: 2–3 d/wk, 150 min, 40% –50% HRR; RT: 2–3 d/wk, 80% 1-RM	16	Supervised/Stage: I, II, III	EX: 35.1 ± 6.1 C: 34.7 ± 6.4	BM, WC, HC, BF, FM, FFM, SBP, DBP, FG, FI, TC, HDL-C, LDL-C, TG, CRP, QoL
(Dieli-Conwright et al., 2022)	BC survivors After treatment	N: 25 EX: 13 C: 12	EX: 59.5 ± 6.5 C: 54.1 ± 10.6 United States	AE+RT, 150 m/wk plus home-based AE 970 min/wk)	24	Supervised & home-based/Stage: I, III	EX: 29.5 ± 3.6 C: 36.4 ± 6.1	BMI, LEP
(Brown et al., 2021)	BC survivors After treatment	N: 177 EX: 87 C: 90	EX: 59.1 ± 8.1 C: 59.0 ± 8.5 United States	AE: 3–6 d/wk, 180 min/wk, 50%–70% HRmax; RT: 2 d/wk, 2–3 sets x 10 reps.	52	Supervised & home-based/Stage: I, III	EX: 34.0 ± 6.2 C: 34.0 ± 5.7	BM, FM, BMD
(Ergun et al., 2013)	BC survivors After treatment	N: 40 EX: 20 C: 20	EX: 49.7 ± 8.35 C: 50.3 ± 10.4 Turkey	AE + RT: for 45 min/D for 3d/wk and brisk walking for 30 min/D for 3 d/wk	12	Supervised/Stage: N/A	EX: 26.6 ± 4.4 C: 28.6 ± 5.2	FA, IL-6, IL-8, TNF-α, QoL, DEP
(Rogers et al., 2013)	BC survivors After treatment	N: 28 EX: 15 C: 13	EX: 58.0 ± 6.1 C: 53.7 ± 13.9 United States	AE: 150 min/wk; RT: 2 d/wk, 60%–70% 1-RM	12	Supervised & home-based/Stage: I, II, III	EX: 33.9 ± 7.4 C: 30.3 ±7.11	BMI, BF, FM, WHR, FA, IL-1β, IL-6, IL-8, IL-10, TNF-α, LEP
(Rogers et al., 2014)	BC survivors After treatment	N: 42 EX: 20 C: 22	EX: 57.2 ± 5.5 C: 55.2 ± 9.1 United States	AE: 160 min/wk; RT: 2 d/wk, 60%–70% 1-RM	12	Supervised & home-based/Stage: I, III	EX: 29.8 ± 4.8 C: 32.6 ± 6.6	FA, BMI, BF, IL-6, IL-8, IL-10, TNF-α, SQ
(Hutnick et al., 2005)	BC survivors After treatment	N: 36 EX: 21 C: 15	EX: 48.5 ± 10.6 C: 52.3 ± 9.2 United States	AE+RT (40–90 min), 3 d/wk, 60%–75% HRmax/1-RM	24	Supervised & home-based/Stage: I, II, III	EX: 26.7 ± 5.45 C: 26.7 ± 4.5	BM, BMI, BF, CRF, IL-6
(Battaglini et al., 2007)	BC patients During treatment	N: 20 EX:10 C: 10	EX 57.5 ± 23.0 C: 56.6 ± 16.0 United States	AE+RT (60 min), 2 d/wk, 40%–60% HRR/1-RM	21	Supervised/Stage: N/A	EX: 77.5 ± 27.3 C: 82.2 ± 25.0	FFM, Muscular Strength
(Mutrie et al., 2007)	BC patients. During treatment	N: 181 EX: 82 C: 95	EX: 51.3 ± 10.3 C: 51.8 ± 8.7 United Kingdom	AE+RT (45 min), 2 d/wk, 50%–75% HRR/1-RM	12	Supervised & home-based/Stage: 0, III	EX: 27.3 ± 5.2 C: 27.5 ± 6.0	BMI, QoL, FA, DEP, Physical Function
(Nieman et al., 1995)	BC survivors After treatment	N: 12 EX: 6 C: 6	EX: 60.8 ± 4.0 C: 51.2 ± 4.7 United States	AE+RT, (60 min), 3 d/wk, 75% HRR/1-RM	8	Supervised / Stage: N/A	EX: 67.6 ± 3.7 C: 75.5 ± 9.8	CRF
(Ligibel et al., 2008)	BC survivors After treatment	N: 82 EX: 40 C: 42	EX: 52.0 ± 9.0 C: 53.0 ± 9.0 United States	AE: 90 min/wk, 2 d/wk; RT: 50 min/wk, 2 d/wk	16	Supervised & home-based/Stage: I, II, III	EX: 30.3 ± 5.9 C: 31.4 ± 6.8	BM, BMI, WC, HC, WHR, BF, LEP, ADPN
(Ligibel et al., 2019)	BC patients Before treatment	N: 48 EX: 26 C: 22	EX: 52.3 ± 9.6 C: 53.1 ± 7.9 United States	AE: 180 min/wk; 60%–70% HRmax; RT: 40 min/wk, 60%–70% 1-RM	16	Supervised & home-based/Stage: I, II, III	EX: 30.7 ± 6.1 C: 29.1 ± 7.4	LEP, CRP, IL-6
(Jones et al., 2020)	BC survivors After treatment	N: 51 EX: 26 C: 25	EX: 55.8 ± 7.2 C: 55.9 ± 7.1 New Zealand	AE+RT (60 min), 2 d/wk	12	Supervised/Stage: I, II, III	EX: 27.8 ± 5.5 C: 27.5 ± 4.8	BM, BMI, FM, BF, SBP, DBP, CRF
(Lee et al., 2019)	BC survivors After treatment	N: 91 EX: 46 C: 45	Total: 53.5 ±10.4 United States	AE: ≥150 min, 2–3 d/wk, 65%–80% HRmax; RT: 2–3 d/wk	16	Supervised/Stage: I, III	BM1 ≥25.0 or BF ≥30%	TC, LDL-C, HDL-C, TG
(Saxton et al., 2014)	BC survivors After treatment	N:85 EX: 44 C: 41	EX: 55.8 ± 10.0 C: 55.3 ± 8.8 United Kingdom	AE: 30 min, 65%–85% HRmax, 3 d/wk; RT: 10–15 min, 2–3 d/wk	24	Supervised/Stage I, III	EX: 29.7±3.5 C: 31.1 ± 5.7	IL-6, TNF-α, NK cell
(Scott et al., 2013)	BC survivors After treatment	N: 83 EX: 43 C: 40	EX: 55.6 ± 10.2 C: 55.9 ± 8.9 United Kingdom	AE: 30 min, 65%–85% HRmax, 3 d/wk; RT: 10–15 min, 2–3 d/wk	24	Supervised/Stage: I, III	EX: 29.6 ± 3.5 C: 31.1 ± 5.6	CRF, SBP, DBP, FG, CRP, TC, HDL-C, LDL-C, QoL, LEP

ADPN: Adiponectin, AE: Aerobic Exercise, BC: Breast Cancer, BF: Body Fat, BM: Body Mass, BMI: Body Mass Index, BMD: Bone Mineral Density, C: Control Group, CART: Combined Aerobic and Resistance Training, CRF: Cardiorespiratory Fitness, CRP: C-Reactive Protein, DBP: Diastolic Blood Pressure, DEP: Depression, EX: Exercise Group, FA: Cancer-related Fatigue, FFM: Fat-Free Mass, FG: Fasting Glucose, FI: Fasting Insulin, FM: Fat Mass, HC: hip circumference, HDL-C: High-Density Lipoprotein Cholesterol, HRmax: Maximum Heart Rate, HRR: Heart Rate Reserve, IL: Interleukin, LEP: Leptin, LDL: Low-Density Lipoprotein Cholesterol, NK: Natural Killer, RT: Resistance Training, SBP: Systolic Blood Pressure, SQ: Sleep Quality, TC: Total Cholesterol, TG: Triglycerides, TNF-α: Tumor Necrosis Factor α, QoL: Quality of Life, WC: Waist circumference, WHR: Waist-to-Hip Ratio, 1-RM: Repetition Maximum.